戻る Agenda
[V4-S3] Innovation in Development of Orphan Drugs (1) — Status Quo of Designation Scheme and Academia
Session Chair(s)
Yasuhiro Kanatani
Director, Dept of Health Crisis Management
National Institute of Public Health, Japan
Satoru Hayata, MS
Sobi Japan, Japan
Speaker(s)
Japan Status on Orphan Designation - Past, Present and Future Views
Daiju Okuda
Ministry of Health, Labour and Welfare, Japan
Evaluation and Licensing Division
Current Situation of Investigator Initiated Development of Orphan Drugs - Approaches from Academia
Masanori Fukushima, MD, PHD
Translational Research Center For Medical Innovation, Japan
Director
An Alternative Approach in Development of Orphan Drugs - KOINOBORI Drug Development Support Program -
Taro Inaba
KOINOBORI Associate Inc., Japan